Reduction of lung metastasis by ImH[trans-RuCI4(DMSO)Im]: Mechanism of the selective action investigated on mouse tumors

Anti-Cancer Drugs

Volumn 10, Issue 1, 1999, Pages 129-138

  Sava, G ^a,b   Clerici, K ^a   Capozzi, I ^a   Cocchietto, M ^a   Gagliardi, R ^a   Alessio, E ^c   Mestroni, G ^c   Perbellini, A ^d  

^a Callerio Foundation   (Italy)

^b Department of Biomedical Sciences ^*  (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d Area Science Park   (Italy)

Author keywords

Metastasis; Ruthenium; Treatment; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; RUTHENIUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; DRUG CLEARANCE; DRUG MECHANISM; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CLEARANCE; LEWIS CARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033033221     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199901000-00016     Document Type: Article

References (30)

1. Clarke MJ. Ruthenium chemistry pertaining to the design of anticancer agents. In: Clarke MJ, ed. Progress in clinical biochemistry and medicine - Non-platinum metal complexes in cancer chemotherapy. Heidelberg: Springer-Verlag 1989: 25-59.
2. Keppler BK, Henn M, Juhl UM, Berger MR, Niebel R, Wagner FE. New ruthenium complexes for the treatment of cancer. In: Clarke MJ, ed. Progress in clinical biochemistry and medicine - Non-platinum metal complexes in cancer chemotherapy. Heidelberg: Springer-Verlag 1989: 41-69.
3. Mestroni G, Alessio E, Sava G, Pacor S, Coluccia M. The development of tumor-inhibiting ruthenium dimethylsulfoxide complexes. In: Keppler BK, ed. Metal complexes in cancer chemotherapy. Weinheim: VCH 1993: 157-85.
4. 4 isomers and prevention of brain involvement on P388 leukaemia and on P388/DDP subline. Eur J Cancer 1993; 29A: 1873-9.
5. 4(DMSO)Im, a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma. Metal Based Drugs 1995; 2: 195-9.
6. 4(DMSO)Im]. Selective inhibition of spontaneous lung metastases by the ruthenium complex. Drug Invest 1994; 8: 150-61.
7. Sava G. Ruthenium compounds in cancer therapy. In: Fricker SP, ed. Metal compounds in cancer therapy. London: Chapman & Hall 1994: 65-91.
8. 4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin Exp Metast 1992; 10: 273-80.
9. Sava G, Pacor S, Bregant F, Ceschia V, Mestroni G. Metal complexes of ruthenium: antineoplastic properties and perspectives. Anti-Cancer Drugs 1990; 1: 99-108.
10. Mestroni G, Alessio E, Sava G, Pacor S, Coluccia M, Boccarelli A. Water soluble ruthenium(III)-dimethyl sulfoxide complexes: chemical behaviour and pharmacological properties. Metal Based Drugs 1993; 1: 41-63.
11. Sava G, Pacor S, Bergamo A, Cocchietto M, Mestroni G, Alessio E. Effects of ruthenium complexes on experimental tumours: irrelevance of cytotoxicity for metastasis inhibition. Chem-Biol Interact 1995; 95: 109-26.
12. 4(DMSO)Im] in the mouse. Clin Exp Metast 1994; 12: 93-100.
13. Puccetti P, Romani L, Fioretti MC. Chemical xenogenization of tumour cells. Trends Pharm Sci 1985; 6: 213-7.
14. 4(DMSO)Im] is not coupled with the induction of chemical xenogenization. Metal Based Drugs 1996; 3: 67-73.
15. Sava G, Capozzi I, Bergamo A, et al. Down regulation of tumor gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex. Int J Cancer 1996; 68: 60-6.
16. Mestroni G, Alessio E, Sava G. New salts of anionic complexes of Ru(III), as antimetastatic and antineoplastic agents. PCT/EP97/03401, 30/06/97.
17. 3. Inorg Chim Acta 1993; 203: 205-17.
18. Kramer K. Effect of dimethylsulfoxide (DMSO) on the electrocardiogram (ECG) in freely moving male BALB/c mice. Gen Pharmac 1995; 26: 1403-7.
19. 4]. Chem-Biol Interact 1991; 78: 223-34.
20. Bregant F, Pacor S, Ghosh S, Chattopadhyay SK, Sava G. Effects of some ruthenium chelates on MCa mammary carcinoma and on TLX5 lymphoma in mice. Anticancer Res 1993; 13: 1007-10.
21. Tamura H, Arai T, Nagose M, Ichinose N. Determination of ruthenium in biological tissue by graphite furnace AAS after solubilizing the sample in tetramethylammonium hydroxyde. Bunseki Kagaku 1992; 41: T13-8.
22. Greig RG, Trainer DI. Shaping future strategies for the pharmacological control of tumor cell metastases. Cancer Metast Rev 1986; 5: 3-14.
23. 4(DMSO)Im] and ruthenium uptake by tumor cells. Anti-Cancer Drugs 1996; 7: 697-702.
24. Sava G, Capozzi I, Clerici K, Gagliardi R, Alessio E, Mestroni G. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metast 1998; 16: 371-9.
25. Sledge GW, Qulali M, Goulet R, Bone PA, Fife R. Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995; 87: 1546-50.
26. Youneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the biphosphonate ibandronate and tissue inhibitor of the metalloproteinase-2. J Clin invest 1997; 99: 2509-17.
27. Umansky V, Schirrmacher V, Rocha M. New insights into tumor-host interactions in lymphoma metastasis. J Mol Med 1996; 74: 353-63.
28. Schadendorf D, Heidel J, Gawlik C, Suter L, Czarnetzki BM. Association with clinical outcome of expression of VLA-I in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 1995; 87: 366-71.
29. Fox SB, Turner GD, Leek RD, Whitehouse RM, Gatter KC, Harris AL. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumour endothelium. Breast Cancer Res Treat 1995; 36: 219-26.
30. Merriman RL, Shackeford KA, Tanzer LR, Campbell JB, Bemis KG. Drug treatment for metastasis of the Lewis lung carcinoma: lack of correlation between inhibition of lung metastasis and survival time. Cancer Res 1989; 49: 4509-16.